You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Medtronic
Colorcon
Merck
AstraZeneca

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,969,786

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,969,786
Title:Trophic hormone fusion protein, preparation method and application thereof
Abstract: Disclosed herein is a gonadotropin fusion protein or a thyroid stimulating hormone fusion protein, a method for preparing the same and use thereof. .beta.-subunit of the gonadotropin or thyroid stimulating hormone is fused to an Fc fragment directly or indirectly through a linker, and .alpha.-subunit binds to the .beta.-subunit via an affinity between the .alpha.-subunit and the .beta.-subunit. The fusion protein has a prolonged half-life and less fluctuating activity.
Inventor(s): Xu; Ting (Jiangsu, CN), Guo; Kangping (Jiangsu, CN), Yun; Lihong (Jiangsu, CN)
Assignee: Suzhou Alphamab Co, Ltd. (Suzhou Jiangsu, CN)
Application Number:14/646,926
Patent Claims:1. A fusion protein comprising a trophic hormone protein having an .alpha.-subunit, a .beta.-subunit and an Fc fragment of an antibody, wherein the .beta.-subunit of the trophic hormone protein is linked to the Fc fragment directly or indirectly via a linker, and the .alpha.-subunit of the trophic hormone protein binds to the .beta.-subunit via intermolecular interactions between the .alpha.-subunit and the .beta.-subunit, wherein the .alpha.-subunit of the trophic hormone is not directly or indirectly linked to an Fc fragment, and wherein the trophic hormone is selected from the group consisting of luteotropic hormone, follicle stimulating hormone, chorionic gonadotropin, and thyroid stimulating hormone.

2. A heterodimeric protein comprising one fusion protein according to claim 1 and an Fc chain, wherein the Fc chain is associated with the Fc fragment in the fusion protein via chemical association.

3. The heterodimeric protein according to claim 2, wherein the heterodimeric protein has the formula: .alpha.FSH@.beta.FSH-L-Fc:Fc, wherein "FSH" refers to follicle stimulating hormone protein, ".alpha." refers to the .alpha.-subunit of the follicle stimulating hormone protein, ".beta." refers to the .beta.-subunit of the follicle stimulating hormone protein, "@" is the intermolecular interaction between the .alpha.-subunit and .beta.-subunit of the follicle stimulating hormone protein, "L" represents direct linking between the .beta.-subunit and Fc fragment or indirect linking via a linker, "Fc" refers to the Fc fragment of an immunoglobulin, and ":" refers to the chemical association between .beta.FSH-L-Fc and Fc.

4. The heterodimeric protein according to claim 2, wherein the heterodimeric protein has the formula: Ta-.alpha.XXX@.beta.XXX-L-Fc:Fc or Ta-Fc:Fc-L-.beta.XXX@.alpha.XXX wherein "XXX" refers to follicle stimulating hormone, ".alpha." refers to the .alpha.-subunit of the follicle stimulating hormone, ".beta." refers to the .beta.-subunit of the follicle stimulating hormone, "@" is the intermolecular interaction between the .alpha.-subunit and .beta.-subunit of the trophic hormone protein, "L" represents direct linking between the .beta.-subunit and Fc fragment or indirect linking via a linker, "Fc" refers to the Fc fragment of an immunoglobulin, ":" refers to the chemical association between .beta.XXX-L-Fc and Fc, and "Ta" refers to a protein purification tag.

5. A pharmaceutical composition comprising the fusion protein according to claim 1, and a pharmaceutically acceptable carrier or excipient.

6. A recombinant expression vector comprising a nucleotide sequence encoding an .alpha.-subunit of a trophic hormone protein, a nucleotide sequence encoding a fusion protein comprising a .beta.-subunit of the trophic hormone protein and an Fc fragment of an antibody, and a nucleotide sequence encoding an Fc fragment of an antibody, wherein each of the proteins is transcribed and translated independently, and the trophic hormone is selected from the group consisting of luteotropic hormone, follicle stimulating hormone, chorionic gonadotropin and thyroid stimulating hormone.

7. A recombinant cell comprising the recombinant expression vector according to claim 6.

8. A method for preparing a heterodimeric protein comprising a fusion protein that comprises a trophic hormone protein having an .alpha.-subunit and a .beta.-subunit and an Fc fragment of an antibody, wherein the .beta.-subunit of the trophic hormone protein is linked to the Fc fragment directly or indirectly via a linker, and the .alpha.-subunit of the trophic hormone protein binds to the .beta.-subunit via intermolecular interactions between the .alpha.-subunit and the .beta.-subunit, wherein the .alpha.-subunit of the trophic hormone is not directly or indirectly linked to an Fc fragment, and wherein the trophic hormone is selected from the group consisting of luteotropic hormone, follicle stimulating hormone, chorionic gonadotropin and thyroid stimulating hormone, and an Fc chain, wherein the Fc chain is associated with the Fc fragment in the fusion protein via chemical association, comprising the step of isolating and purifying a mixture of heterodimeric proteins and homodimeric proteins, wherein the homodimeric proteins comprise two fusion proteins, wherein each fusion protein comprises a trophic hormone protein having an .alpha.-subunit and a .beta.-subunit and an Fc fragment of an antibody, wherein the .beta.-subunit of the trophic hormone protein is linked to the Fc fragment directly or indirectly via a linker, and the .alpha.-subunit of the trophic hormone protein binds to the .beta.-subunit via intermolecular interactions between the .alpha.-subunit and the .beta.-subunit, wherein the .alpha.-subunit of the trophic hormone is not directly or indirectly linked to an Fc fragment, and wherein the trophic hormone is selected from the group consisting of luteotropic hormone, follicle stimulating hormone, chorionic gonadotropin and thyroid stimulating hormone, and wherein the Fc fragments in the two fusion proteins are associated with each other via chemical association to obtain the heterdimeric protein.

9. The fusion protein according to claim 1, wherein the trophic hormone is follicle stimulating hormone.

10. The fusion protein according to claim 9, wherein the follicle stimulating hormone .alpha.-subunit comprises a sequence according to SEQ ID NO: 1.

11. The fusion protein according to claim 9, wherein the follicle stimulating hormone .beta.-subunit linked to the Fc fragment comprises a sequence according to SEQ ID NO:4.

12. The fusion protein according to claim 9, wherein the follicle stimulating hormone .alpha.-subunit comprises a sequence according to SEQ ID NO:1 and the follicle stimulating hormone .beta.-subunit linked to the Fc fragment comprises a sequence according to SEQ ID NO:4.

13. The fusion protein according to claim 1, wherein the Fc fragment comprises a hinge region, a CH2 domain, and a CH3 domain of an immunoglobulin.

14. The fusion protein according to claim 1, wherein the Fc fragment comprises an IgG1 Fc.a.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
China2012 1 0476665Nov 22, 2012
PCT Information
PCT FiledNovember 22, 2013PCT Application Number:PCT/CN2013/087676
PCT Publication Date:May 30, 2014PCT Publication Number:WO2014/079384

Details for Patent 9,969,786

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 004 1975-06-26   Start Trial Suzhou Alphamab Co, Ltd. (Suzhou Jiangsu, CN) 2032-11-22 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 006 1975-06-26   Start Trial Suzhou Alphamab Co, Ltd. (Suzhou Jiangsu, CN) 2032-11-22 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 007 1975-06-26   Start Trial Suzhou Alphamab Co, Ltd. (Suzhou Jiangsu, CN) 2032-11-22 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 009 1975-06-26   Start Trial Suzhou Alphamab Co, Ltd. (Suzhou Jiangsu, CN) 2032-11-22 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 010 1975-06-26   Start Trial Suzhou Alphamab Co, Ltd. (Suzhou Jiangsu, CN) 2032-11-22 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 011 1975-06-26   Start Trial Suzhou Alphamab Co, Ltd. (Suzhou Jiangsu, CN) 2032-11-22 RX search
Bel Mar CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017054 001 1974-03-26   Start Trial Suzhou Alphamab Co, Ltd. (Suzhou Jiangsu, CN) 2032-11-22 DISCN search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Harvard Business School
Merck
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.